Blood Grouping Reagents

Blood Grouping Reagents

The Blood Grouping Reagents market is expected to register a CAGR of approx. 7% over the period of 2022-2030. The blood grouping reagents market refers to the segment of the healthcare industry that deals with the production, distribution, and sale of reagents used for blood typing and cross-matching in blood transfusion and transplantation procedures. Blood grouping reagents are substances or mixtures used in laboratory settings to determine an individual's blood group (such as A, B, AB, or O) and Rh factor (positive or negative) by detecting specific antigens and antibodies present on red blood cells. These reagents play a crucial role in ensuring safe and compatible blood transfusions, as well as in identifying potential risks of transfusion reactions. The growing demand for blood grouping reagents can be attributed to the increasing demand for blood transfusion around the globe. For Instance, according to givingblood.org, in 2023, 4.5 million Americans will need blood transfusion each year. 43,000 pints amount of donated blood is used each day in the U.S. and Canada. Furthermore, the blood grouping reagent market has witnessed the prevalence of blood-related disorders, such as anaemia, haemophilia, and blood cancers, increasing globally. These conditions often require regular blood transfusions, creating a higher demand for blood grouping reagents to ensure compatibility and prevent adverse reactions. Rising healthcare expenditure and investments in healthcare infrastructure, particularly in developing countries, contribute to the growth of the blood grouping reagents market. However, some of the restraints in the market, including the high costs of advanced reagents and stringent regulations are impeding the growth of this market all over the world.

• Based on the product, the market has been categorized into consumables and instruments. Among them, the consumables segment is expected to grow at the highest CAGR in the market due to the increase in surgical procedures such as organ transplantation and the use of serological fluids and reagents in laboratories. The growth can also be attributed to the high blood donation rates leading to increased blood sample analysis. Additionally, the development of new molecular diagnostic test reagents and kits focused on reducing the turnaround time needed for conclusive outcomes is expected to further facilitate the growth.
• Based on the test type, the market has been categorized into antibody screening, HLA typing, cross-matching tests, abo blood tests, and antigen typing. Among them, the antibody screening segment is expected to grow at a higher CAGR in the market due to the increasing demand for early diagnosis and the rising prevalence of chronic disorders. Moreover, the increasing incidence of Transfusion Transmitted Infections (TTIs), particularly in lower-middle-income and low-income nations is one of the major factors driving the segment growth.
• Based on the end-users, the market has been categorized into hospitals, blood banks, and clinical laboratories. Among them, the hospitals category is to witness higher adoption of blood grouping reagents during the forecast period. This growth can be attributed to the increasing awareness on blood donations and their importance, rising number of blood donations, and growing requirement of blood in surgical treatments.
• For a better understanding of the market adoption of blood grouping reagents, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of APAC), and Rest of World. Blood grouping reagents have gained increasing popularity in North America due to various factors. The North America Blood Grouping Reagents market is expected to grow in the coming years, driven by the high prevalence of chronic diseases, an ageing population, and a large number of surgical procedures. This drives the need for accurate blood grouping and cross-matching using blood grouping reagents. Moreover, North America is known for its advanced healthcare systems and technological innovations. The region has witnessed the adoption of automated blood typing systems and point-of-care testing devices, which require compatible blood grouping reagents. These advancements improve efficiency, accuracy, and patient outcomes. Furthermore, North America has witnessed collaborations and partnerships between blood banks, healthcare providers, and manufacturers of blood grouping reagents. These collaborations aim to enhance research, development, and adoption of advanced blood grouping reagents, further driving market growth. For instance, in 2021, Bio-Rad Laboratories announced a partnership with Seegene, to manufacture and commercialize molecular diagnostic equipment for infectious diseases.
• Some of the major players operating Agena Bioscience Inc, Alpha Laboratories, Arena BioScien, Atlas Medical GmbH, Bio Rad Laboratories Inc, Haemokinesis Ltd, Merck KGaA, Grifols, S.A., Immucor, Inc., Rapid Labs Ltd. among others. Several M&A’s along with partnerships have been undertaken.